加载中
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
前收盘价
US$28.28
+US$0.46 · +1.65%
盘前
US$28.34
+US$0.06 · +0.21%
10月12日 4:03 ET
盘中时间采用ET。市场数据可能有所延迟。
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
日内区间
当前US$28.28
52周区间
当前US$28.28
盘中时间采用ET。市场数据可能有所延迟。
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
日内区间
当前US$28.28
52周区间
当前US$28.28
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 625.79亿 USD | 636.27亿 USD | 595.53亿 USD | 1003.3亿 USD | 812.88亿 USD |
| 销货成本 | 185.65亿 USD | 217.81亿 USD | 292.13亿 USD | 382.4亿 USD | 344.13亿 USD |
| 毛利 | 440.14亿 USD | 418.46亿 USD | 303.4亿 USD | 620.9亿 USD | 468.75亿 USD |
| 研究与开发 | 119.76亿 USD | 107.38亿 USD | 105.78亿 USD | 114.26亿 USD | 138.28亿 USD |
| 销售、一般及管理费用 | 133.46亿 USD | 147.3亿 USD | 144.7亿 USD | 131.15亿 USD | 122.54亿 USD |
| 营业费用 | 285.77亿 USD | 253.63亿 USD | 250.48亿 USD | 245.41亿 USD | 260.82亿 USD |
| 利息收入 | 6.03亿 USD | 5.45亿 USD | 16.24亿 USD | 2.51亿 USD | 3600万 USD |
| 利息支出 | 26.71亿 USD | 30.91亿 USD | 22.09亿 USD | 12.38亿 USD | 12.91亿 USD |
| 折旧和摊销 | 65.92亿 USD | 70.13亿 USD | 62.9亿 USD | 50.64亿 USD | 51.91亿 USD |
| 营业利润 | 154.37亿 USD | 164.83亿 USD | 52.92亿 USD | 375.49亿 USD | 207.93亿 USD |
| 净利润 | 77.7亿 USD | 80.2亿 USD | 21.33亿 USD | 313.65亿 USD | 221.47亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$29.17
上涨空间 3.15%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2020年11月17日 | 527:500 | — | — |
股票拆分 | 1999年7月1日 | 3:1 | — | — |
股票拆分 | 1997年7月1日 | 2:1 | — | — |
股票拆分 | 1995年7月3日 | 2:1 | — | — |
股票拆分 | 1991年4月1日 | 2:1 | — | — |
股票拆分 | 1983年7月1日 | 2:1 | — | — |
已生效 2020年11月17日
527:500
已生效 1999年7月1日
3:1
已生效 1997年7月1日
2:1
已生效 1995年7月3日
2:1
已生效 1991年4月1日
2:1
已生效 1983年7月1日
2:1
报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T3067.24亿0.24%129.43万亿 JPY0.09%JP¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI51.55亿0.22%2.3万亿 USD0.03%US$381.94+0.63%
Vanguard S&P 500 ETFVOO43.1亿0.24%1.8万亿 USD0.03%US$715.59+0.61%
iShares Core S&P 500 ETFIVV21.08亿0.24%8964.4亿 USD0.03%US$781.97+0.60%
State Street SPDR S&P 500 ETFSPY19.37亿0.24%8172亿 USD0.09%US$778.57+0.60%
Vanguard Morningstar Value ETFVTV15.5亿0.59%2624亿 USD0.03%US$220.59+0.44%
State Street Health Care Select Sector SPDR ETFXLV11.29亿2.59%435.37亿 USD0.08%US$170.81+1.58%
Vanguard High Dividend Yield ETFVYM6.57亿0.65%1008亿 USD0.04%US$158.75+0.32%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYVanguard Morningstar Value ETFVTVState Street Health Care Select Sector SPDR ETFXLVVanguard High Dividend Yield ETFVYMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
